20.500.12556/DiRROS-23999 Analysis of informed consent forms of patients undergoing cancer genetic testing in the era of next-generation sequencing The Department of Clinical Cancer Genetics at the Institute of Oncology Ljubljana offers genetic counselling and testing to cancer patients and their relatives. Before undergoing genetic testing, patients sign the informed consent form. In addition to giving consent for collection of biological material and genetic testing, patients decide about storage of biological material and participation in international databases. Furthermore, patients decide whether the information regarding their test results may be revealed to their blood relatives and whether they want to be informed about secondary findings. Methods Using the signed consent forms, we investigated the effect of selected factors on patients’ decisions. Using different statistical methods, we tried to determine the proportion of patients who opted for different items and the effect of gender, age and cancer diagnoses on their decisions. Results Nearly all (99.6%) patients, regardless of gender, age, and presence of oncological diagnosis, consented to the storage of their biological material, 98.4% of patients, regardless of gender, age, and presence of oncological diagnosis, wanted to be included in international databases in a pseudo-anonymised form, 98.8% of patients, irrespective of gender, age, and presence of oncological diagnosis, allowed blood relatives to see their results, and 98.4% of patients, irrespective of gender, age and presence of oncological diagnosis, wanted to know whether secondary findings were detected when genetic analysis of their biological material was performed. Men are, on average, more likely to consent but the difference between genders is not statistically significant. Patients without oncological disease were more likely to agree to be included in international databases than patients with a confirmed oncological diagnosis. Conclusions Our results show that the vast majority of patients were in favour of the options they were offered. Most importantly, the majority of them allow their genetic test results be revealed to their blood relatives when needed and would participate in international databases. Research in rare diseases, including rare cancer genetic predisposition syndromes, is crucial for optimal diagnostic, prevention and treatment options for patients with rare genetic disorders. The results are also important for refining the approach to pre-and post-test cancer genetic counselling. informed consent genetic counselling genetic testing informirano soglasje genetsko svetovanje genetsko testiranje true false true BioMed Central Ltd (Springer Nature) Angleški jezik Slovenski jezik by Authors Neznano 2025-11-06 03:38:19 2025-11-19 14:14:52 2025-11-20 03:44:35 0000-00-00 00:00:00 2025 0 0 Nasl. z nasl. zaslona; Opis vira z dne 8. 10. 2025; 9 str. Vol. 23 2025 0000-00-00 Zaloznikova Objavljeno apc 2024-11-15 2025-02-13 2025-02-21 616-07 1897-4287 10.1186/s13053-025-00309-8 227017219 RAZ_Kersevan_Tina_2025.pdf RAZ_Kersevan_Tina_2025.pdf 1 4B7A9287B2FFDE537FBDA4B59B06C96E e9f372700529f1407915c7d04f6c444cb3751fc30e527d884918ebe021fd0c50 30e2039e-c549-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=36034 https://hccpjournal.biomedcentral.com/articles/10.1186/s13053-025-00309-8 1 a8293b27-bab9-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=35651 Onkološki inštitut Ljubljana 0 0 0